Author

Nichola Erler-Yates

Observed name: Erler-Yates, Nichola

Observed institutions: Gachon University, Janssen (Germany), Cilag (Switzerland)

OpenAlex ID: A5065375628

Adjusted comparison of outcomes between patients from CARTITUDE-1 versus multiple myeloma patients with prior exposure to proteasome inhibitors, immunomodulatory drugs and anti-CD38 antibody from the prospective, multinational LocoMMotion study of real-world clinical practice

2022 · Maria-Victoria Mateos, Katja Weisel, et al. · Haematologica · 21

Real-World Treatment Patterns, Healthcare Resource Use and Disease Burden in Patients with Multiple Myeloma in Europe

2023 · Joaquín Martínez-Lopez, Abigail Bailey, et al. · Future Oncology · 13

Ciltacabtagene Autoleucel for Triple-Class Exposed Multiple Myeloma: Adjusted Comparisons of CARTITUDE-1 Patient Outcomes Versus Therapies from Real-World Clinical Practice from the LocoMMotion Prospective Study

2021 · Maria-Victoria Mateos, Katja Weisel, et al. · Blood · 11

Patient Characteristics and Survival Outcomes of Lenalidomide Exposed non- Refractory vs. Lenalidomide Refractory Multiple Myeloma Patients in the HONEUR Federated Data Network

2022 · Roman Hajek, Henrik Sliwka, et al. · Blood · 7

P-244 Teclistamab versus Belgian real-world clinical practice in triple-class exposed relapsed and refractory multiple myeloma patients using adjusted comparison

2023 · Michel Delforge, Sébastien Anguille, et al. · Clinical Lymphoma Myeloma & Leukemia · 1

P979: Patient-reported Outcomes for Teclistamab Versus Real-world Physician’s Choice of Therapy in the Locommotion Study in Patients With Triple-class Exposed Relapsed/refractory Multiple Myeloma

2023 · Philippe Moreau, Niels W.C.J. van de Donk, et al. · HemaSphere · 1

PA-402 Real-world Outcomes in Smoldering Multiple Myeloma in Europe: Updated results from the SPARK Study

2026 · Francesca Gay, Ido Lapidot, et al. · Clinical Lymphoma Myeloma & Leukemia

P922: Adjusted Comparisons of Ciltacabtagene Autoleucel With Therapies From Real-world Clinical Practice: Two-year Follow-up Analyses From Cartitude-1 and the Prospective Locommotion Study

2023 · Maria-Victoria Mateos, Katja Weisel, et al. · HemaSphere

Works count: 9

Citation count: 54

H-index: 4

I10-index: 3